Bradley D. Hunter

Join Dr. Onyee Chan, a hematologist-oncologist specializing in myeloid malignancies, and Dr. Bradley D. Hunter, a physician-scientist and medical director, as they dive into the latest advancements in chronic myeloid leukemia (CML) management. They emphasize the importance of integrating asciminib as a first-line therapy and discuss optimal treatment sequencing. Key insights include the impact of the OPTIC trial on ponatinib dosing strategies and the role of mutational testing in personalizing patient care. The dialogue also explores the evolving relevance of stem cell transplantation in treatment.